Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed soft tissue sarcoma (STS) for which neoadjuvant or adjuvant radiotherapy is considered standard care~  * Stage IB-III disease~ * Primary or locally recurrent disease~* The following chemotherapy-sensitive STS histologies are excluded:~  * Primitive neuroectodermal tumor~ * Desmoplastic small round cell tumor~ * Synovial sarcoma~ * Myxoid round cell liposarcoma~ * Angiosarcoma~* No sarcomas for which surgical staging and adjuvant radiotherapy are considered standard care (e.g., uterine sarcomas, including leiomyosarcoma, malignant mixed Müllerian tumors, and endometrial stromal sarcoma)~* No retroperitoneal STS~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Able to complete the self-assessment questionnaires (may use translator service)~* Willing and able to undergo pre-treatment core needle biopsies~* Negative pregnancy test~* No known HIV positivity~PRIOR CONCURRENT THERAPY:~* Prior adjuvant chemotherapy for STS allowed provided patient has locally recurrent disease~  * At least 1 year since prior adjuvant chemotherapy~* No prior radiotherapy to the site of present STS~* No other concurrent cytotoxic chemotherapy, targeted therapy, or investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.

Based on this trial design, predict the completion outcome and termination type (if applicable).